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Commentaries

TREATING TOBACCO ADDICTION IN
SCHIZOPHRENIA: WHERE DO WE GO
FROM HERE?
The paper by McChargue et al. (2002) raises an important question regarding the treatment of tobacco addiction in schizophrenia—whether smoking abstinence or
smoking reduction should be the ultimate goal. The
authors discuss four published studies combining
pharmacotherapy and psychosocial interventions for
smoking cessation/reduction in schizophrenic smokers,
and conclude that rates of smoking abstinence at trial
end-point and 6-month follow-up assessment are much
lower in these patients compared to the general population. Accordingly, they reason that smoking reduction
might be a more realistic outcome for schizophrenics,
especially since they may derive benefits from nicotine
use for clinical and cognitive deficits associated with this
disorder.
There are several important issues with respect to
smoking reduction versus abstinence approaches for
tobacco use in schizophrenia. First, harm reduction
approaches have not been documented to decrease or
eliminate the risk of developing smoking-related medical
illnesses in either non-psychiatric or psychiatric smokers
(Hughes 1998). This is important because schizophrenic
patients seem to be at higher risk for developing cardiovascular disease and lung cancer compared to controls
(Tsuang, Perkins & Simpson 1983; Lichterman et al.
2001). Secondly, while there seems to be growing evidence that many of the clinical and cognitive deficits in
schizophrenia may be alleviated by nicotine/smoking
(Adler et al. 1993; Dalack et al. 1998; George et al. 2002),
and that nicotinic receptor function may be abnormal in
the disorder (Freedman et al. 1997; Breese et al. 2000),
one of the strongest environmental cues that promotes
continued smoking is the act of smoking itself. As
smoking cues promote smoking urges in schizophrenics
(Tidey et al. 2001), it seems highly unlikely that longterm reductions in smoking behavior can be achieved in
this population. Thirdly, an important variable that has
emerged as a positive predictor of smoking reduction/
cessation in this population is the use of clozapine
(George et al. 1995; McEvoy et al. 1995) and other atypical antipsychotic agents. Atypical antipsychotic drugs
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have been shown to produce a sustained amelioration of
sensory gating deficits associated with schizophrenia
(Nagamoto et al. 1996; Light et al. 2000), and of negative symptoms and some neuropsychological deficits
(Meltzer, Park & Kessler 1999), in contrast to nicotine,
that produces transient effects on these outcomes due to
nicotinic receptor desensitization (Leonard et al. 2000).
Hence, these positive effects of medications for schizophrenia on smoking suggest that optimizing pharmacological treatments for schizophrenia with those for
treatment of nicotine dependence (nicotine replacement,
bupropion), in combination with modified behavioral
treatments, may lead to enhanced smoking cessation
outcomes, as observed in one study (George et al. 2000).
In that study, long-term smoking abstinence in schizophrenics was linked to achievement of abstinence early
in the treatment trial (George et al. 2000), as has been
shown in treatment studies of non-psychiatric smokers.
Fourthly, the fact that trial end-point smoking abstinence
is not enduring at 6-month follow-up assessment is
not surprising, as high attrition in smoking abstinence
is also seen in studies with non-psychiatric smokers
(Hughes et al. 1999). The extended use of available
treatments (nicotine replacement, bupropion) combined
with relapse–prevention therapy may enhance long-term
cessation outcomes in schizophrenic smokers.
Thus, it seems premature to conclude that the goal of
reducing smoking should be recommended for treating
smoking in schizophrenia. However, smoking reduction
as a transition to abstinence needs more careful evaluation in this population. More data are needed about the
effects of reducing smoking on biomarkers associated
with the development of smoking-related medical illness,
as well as on whether reducing smoking (compared to
not reducing) decreases their incidence. Development of
nicotinic receptor agonists (not nicotine) that are safe for
use in humans may also assist these patients in achieving long-term smoking abstinence, and remediate clinical and cognitive deficits that accompany schizophrenia.
The authors are to be commended on their balanced discussion of this topic and for advocating that multiple
smoking treatment strategies need to be evaluated in this
population. The increasing interest by investigators, and
the growing number of funded studies in this area,
should greatly improve such treatment in the future.
Addiction, 97, 795–800
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YES! SMOKERS WITH SCHIZOPHRENIA
WILL BENEFIT FROM MORE FLEXIBLE
TREATMENT APPROACHES
McChargue, Gulliver & Hitsman (2002) present a timely
and insightful argument suggesting that individuals
with schizophrenia might benefit from a more flexible
approach to smoking treatment. Given the serious health
consequences and weak efficacy of current treatments
of tobacco smoking in this population (McChargue et al.
2002), new and more flexible approaches are warranted.
More specifically, McChargue et al. suggest that the
potential utility of reduction-focused approaches to
tobacco treatment should be evaluated in schizophrenics
because strong psychobiological factors undermine their
quit attempts. The three reduction techniques suggested
are: (1) limiting access to cigarettes, (2) reinforcing
lowered smoking rates and (3) providing nicotine
replacement. These suggestions are well justified in their
article and may prove to be important steps towards a
comprehensive approach to smoking risks in schizophrenics. The following comments are meant to support,
extend and amplify these suggestions.
The high smoking-relapse rates, chaotic life-styles,
limited cognitive and social resources and limited alternative reinforcers characteristic of schizophrenics make
Addiction, 97, 795–800
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it important to address systematically the duration and
generalization of smoking treatment effects in these
individuals. While McChargue et al. note briefly the generalization problem, specific methods to enhance generalization are not addressed in their important review. The
failure of treatment effects to generalize across time and
settings is common for all forms of drug and behavior
therapy (Plaud & Eifert 1998) and is likely to be especially
problematic with schizophrenics attempting to quit
smoking. Generalization problems are associated with
limiting access to cigarettes, the first of the three suggestions. While such access limitations may help reduce
smoking rate and exposure to tobacco toxins in in-patient
settings, in-patient limits are unlikely to promote longterm reductions in out-patient settings unless out-patient
treatment also limits access or assures other environmental and/or pharmacological (NRTs or other) support. Thus, the long-term effectiveness of a limitations
approach may require the involvement of family, social
and out-patient resources, as undertaken in the case of
some drug treatments and in the case of dialectical
behavior therapy for the treatment of borderline disorders (Linehan 1993). Such a social–therapeutic system
might use both restricted access to cigarettes and reinforcement procedures (McChargue et al.’s second suggestion) for smoking reduction or abstinence. However,
given the limited resources of the health-delivery system,
a comprehensive social–therapeutic system capable of
restricting cigarette access effectively and providing reinforcement for lowered tobacco consumption will not
be viable for many, if not most individuals with schizophrenia. This leads to the practical question of what
economically feasible alternatives might be created for
this population with strong motivations to smoke and
minimal motivation to quit.
If individuals with schizophrenia find smoking to be
highly reinforcing and have few alternative competing
reinforcers, it may be desirable to develop new and relatively safe nicotine replacement therapies (NRTs) that are
more reinforcing than current NRTs. The development of
inexpensive, alternative nicotine replacement therapies
that provide smoking-equivalent, phasic boluses of nicotine (or functionally equivalent, yet less dangerous drug)
with fingertip control of nicotine timing and dose would
almost certainly be of more reinforcement value than
current NRTs. Of course, such NRTs would need to
minimize toxic effects associated with tobacco cigarettes.
Unlike currently available nicotine replacement therapies, cigarettes provide fingertip and immediate control
over nicotine dose and sensory effects (Ashton, Stepney
& Thompson 1979). Given the low economic status of
most individuals with schizophrenia, NRTs will need to
address the cost the NRT product, relative to the cost of
relatively inexpensive tobacco cigarettes.
© 2002 Society for the Study of Addiction to Alcohol and Other Drugs
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Finally, to the degree that individuals with schizophrenia are self-medicating schizophrenic symptoms
and effects of long-term medication treatment, NRT
will have to compete with smoking benefits over a protracted length of time if they are to provide sustained
reductions in smoking rate and relapse. Thus, flexible
approaches may need to include effective (rapid and substantial dose and finger-tip control) and less hazardous
means of nicotine administration over prolonged periods
of time.
In summary, the challenges of developing effective
treatments for individuals with schizophrenia are at least
as great as those outlined by McChargue et al. Their suggested smoking-reduction approach needs to be evaluated empirically and extended in a variety of directions.
New and creative NRTs and pharmacological and psychosocial interventions are needed to compete with the
high reinforcement value of smoking in schizophrenics.
McChargue et al. are to be applauded for suggesting some
initial steps that may prove useful in the march toward
the reduction of smoking-induced harm in a group with
few resources to counter the enticement of tobacco
smoking. In addition, their neurobiological model of
smoking reinforcement in schizophrenics incorporates
many of the most current models of smoking motivation
(Gilbert & Gilbert 1998; Hughes 1999) and recognizes
the importance of a comprehensive model of intervention that incorporates individual differences in environment and personal vulnerabilities.
DAVID G. GILBERT
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RIGIDITY IN MEASURES OF
SMOKING CESSATION
I and others before me (Henningfield 1994) believe that
tobacco researchers have become overly rigid on insisting
that long-term abstinence (LTA) is the gold standard for
evaluating smoking cessation and interventions.
One major function of an treatment outcome is to
detect efficacy. LTA is an insensitive measure to detect efficacy because it is a dichotomous outcome which poses a
high hurdle. For example, if studies of antidepressants
used ‘the incidence of absence of any depressive symptoms over the last 6 months’ as their major outcome
many current treatments would have been deemed failures. This high hurdle is especially problematic when
new treatments are studied. It is highly probable that
early tests of a new treatment choose the wrong dose, etc.
and produce a weak treatment effect that could be
improved, yet these treatments are discarded because this
weak effect is not detected by LTA.
LTA is also insensitive because it fails to measure
other possible benefits of treatment. For example, policy
interventions (US Department of Health and Human
Services 2000) and cessation treatments (Hughes 2000)
often decrease the number of cigarettes/day among
non-abstaining adults. Recent findings suggest such
reductions do improve health (Nordstrom et al. 2000). As
another example, a smoker’s longest period of previous
abstinence is a powerful predictor of eventual cessation
(Gilpin et al. 1997). Perhaps one effect of our treatments
is to induce a longer period of abstinence which translates to eventual cessation months later.
Clearly, the smoking cessation field needs to begin to
explore the relationship of these less ambitious, more
sensitive measures with eventual LTA. If these measures
were adequate proxies for LTA, this could greatly decrease
the time and cost to screen new treatments or to improve
the delivery of proven treatments.
Another function of an outcome measure is to indicate health benefit. One of the major rationales for
LTA is that it is clear that LTA improves health (US
Department of Health and Human Services 1990).
However, given the strong dose–response relationship
between smoking and mortality (US Department of
Health and Human Services 1990), logically the best
measure of health impact in a population should be the
total exposure to tobacco toxins (Stratton et al. 2001).
This could be indexed by total number of cigarettes
smoked over a certain period. However, since reductions
in cigarettes/day are likely to be accompanied by increases in intensity of smoking of the remaining cigarettes (Stratton et al. 2001), an alternative would be the
average level of some biomarker of smoke intake over
time (Stratton et al. 2001).
© 2002 Society for the Study of Addiction to Alcohol and Other Drugs

So why have tobacco researchers been so fixated on
LTA? I think it is for three reasons: (l) LTA is thought
to be verifiable and thus more scientific (although some
disagree; Velicer et al. 1992); (2) non-LTA outcomes
such are reduction in cigarettes/day are thought not
to be maintained (although some disagree; Hughes
2000); and (3) LTA is thought to be a conservative
outcome (although some argue overly conservative outcomes are problematic; Cohen 1994).
In summary, I would encourage authors of cessation
studies to report several non-LTA as well as LTA outcomes
and reviewers and editors to allow authors the space for
these to be reported. Only then can we assess whether
LTA is best conceived of as the gold standard or the ‘gold
wish’ (Henningfield 1994).
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A REPLY TO THE COMMENTARIES ON
SCHIZOPHRENIA AND SMOKING
TREATMENT: MORE RESEARCH IS
NEEDED
Our paper (McChargue, Gulluver & Hitsman 2002)
explores whether patients with schizophrenia need to
change smoking behavior at a slower rate and require
greater reinforcement for change in order to compensate for any abnormal neurobiological factors that may
undermine quit attempts. A review of the literature suggests that an alternative smoking treatment for people
with schizophrenia draws upon a harm reduction model,
which emphasizes skill acquisition and prompts abstinence once reduced exposure to tobacco toxins have been
obtained and stabilized over time.
The commentaries echo the importance of the question about how to treat smokers with comorbid schizophrenia. The overall consensus is that consideration
of alternative approaches is a valid direction to pursue.
However, some caution should be taken when evaluating
alterative approaches. The primary concern from the
commentaries involves the role harm reduction should
play in the treatment of smokers with schizophrenia.
To clarify our position, we do not advocate that abstinence-based treatments be abandoned. Our hope is that
future research will show more efficacious outcomes
resulting from abstinence-based treatments. As George &
Vessicchio (2002) suggest, newer and more innovative
abstinence-based smoking treatments are being developed that target individuals with schizophrenia. For
example, a recent study reports 50% short-term abstinence rates among smokers with schizophrenia who
received 300 mg/day of bupropion SR in a placebocontrolled smoking treatment trial (George et al. 2002).
One issue that continues to plague smoking treatments for individuals with schizophrenia is the lack of
data. For example, it is still unclear whether smokers
with schizophrenia are capable of long-term abstinence.
We concur with some of the commentators that future
smoking treatments incorporate reports of long-term
abstinence. However, we are not convinced that longterm abstinence, if achievable for this population, should
be routed solely through traditional abstinence-based
efforts. Nor are we convinced that harm reduction should
be the ultimate goal for this subgroup of smokers. At the
very least, we suggest that harm reduction techniques be
used as a transitional step to abstinence.
To date, harm reduction approaches applied to
smokers with schizophrenia remain more conceptual
© 2002 Society for the Study of Addiction to Alcohol and Other Drugs
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than empirical. The commentaries address many important issues for researchers to consider when evaluating
these approaches. First, more data are needed showing
that smoking reduction corresponds with reduced biomarkers (George & Vessicchio 2002). In fact, we agree
with Hughes (2002) that reduced biomarkers may be a
more appropriate measure of harm reduction effects
rather than the number of cigarettes smoked per day.
Secondly, the evaluation of treatment duration and generalization should also be considered (Gilbert 2002). As
Gilbert discusses, in-patient populations are very different from out-patient populations. Harm-reduction techniques are easier to implement in in-patient settings. In
contrast, out-patient smokers have different social and
environmental influences that may hinder or help harm
reduction efforts. Given the inherent differences between
in-patients and out-patients, we concur that treatment
approaches should be tailored. Thirdly, the use of nicotine replacement therapies (NRT) has been the most
widely espoused technique for harm reduction. Many
suggest that NRTs be administered for long periods
of time and at higher doses. Nevertheless, we concur
with Gilbert (2002) in that, if NRTs are considered,
researchers should assess the accrued monetary cost of
such interventions.
In conclusion, many unanswered questions remain.
Our hope is that this ‘for debate’ series will start a dialog
about how to address extremely difficult to treat underrepresented smoking populations. As reflected in many of
the commentaries as well as the original paper, much
research is needed to adequately evaluate smoking treatment for individuals with schizophrenia. The extent to
which harm reduction approaches represent a viable
alternative remains to be seen.
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